Search

Displaying results 521 - 530 of 4339 in total
  1. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    [L42975] In 1963, metamizole was withdrawn from the Canadian market and banned in the UK, France, Sweden, Norway and Australia.

    Mixtures: DIPIRONA SODICA / ISOMETEPTENO MUCATO/CAFEINA 300 MG / 30 MG/30MG TABLETA RECUBIERTA
  2. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.

  3. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the

    Mixtures: IMPLICOR 50MG/5MG FILM-COATED TABLETS, IMPLICOR 50MG/7.5MG FILM-COATED TABLETS
  4. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

    Products: Spedra 50mg Tablets, SPEDRA TABLET 50MG
  5. Drug

    Chlorobutanol

    go.drugbank.com/drugs/DB11386
    ApprovedVet approvedWithdrawn

    Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.

    Mixtures: NOSTIL 75 MG/60MG/35MG BURUN SPREYİ, ÇÖZELTİ, 15 ML
  6. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

  7. Drug

    Dydrogesterone

    go.drugbank.com/drugs/DB00378
    ApprovedInvestigationalWithdrawn

    A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

    Mixtures: FEMOSTON 1/10MG, FEMOSTON 1/10MGProducts: DUPHASTON 10MG, DUPHASTON 10MG FTA
  8. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.

  9. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.

  10. Drug

    Menadione

    go.drugbank.com/drugs/DB00170
    ApprovedNutraceutical

    A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.